A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
Status:
Completed
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of KA34 when administered via
intra-articular injection to subjects with osteoarthritis of the knee.
Phase:
Phase 1
Details
Lead Sponsor:
Calibr, a division of Scripps Research California Institute for Biomedical Research
Collaborator:
California Institute for Regenerative Medicine (CIRM)